Loading…
Loading…
EQUITY / NASDAQ · XNCM
Aprea Therapeutics, Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗0.73 USD · -2.6667%
Observed: Sep 30, 2026, 11:52 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 0.75 USD · Volume 582,214
21 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Cash and cash equivalents | 41,233,428 USD | 16,532,199 USD | +149.41% |
| Net income | -3,591,304 USD | -3,238,870 USD | — |
| Operating profit | -4,032,180 USD | -3,387,773 USD | — |
| Total assets | 42,289,924 USD | — | — |
| Total equity | 38,470,261 USD | 13,414,681 USD | +186.78% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 41,233,428 USD | — | — | 14,599,347 USD | 14,599,347 USD | 13,718,052 USD | — | 16,532,199 USD |
| Net incomeIncome statement | -3,591,304 USD | -6,879,221 USD | -3,287,917 USD | — | -12,599,569 USD | -2,972,410 USD | -10,143,939 USD | -3,238,870 USD |
| Operating profitIncome statement | -4,032,180 USD | -7,462,592 USD | — | — | -13,233,836 USD | -3,117,388 USD | -10,590,743 USD | -3,387,773 USD |
| Total assetsBalance sheet | 42,289,924 USD | — | — | 15,933,401 USD | 15,933,401 USD | 14,321,316 USD | — | — |
| Total equityBalance sheet | 38,470,261 USD | — | 41,588,380 USD | 12,441,682 USD | 12,441,682 USD | 10,912,848 USD | — | 13,414,681 USD |
| Capital expendituresCash flow statement | — | 15,400 USD | — | — | — | — | — | — |
| Financing cash flowCash flow statement | — | 32,686,442 USD | — | — | 4,640,238 USD | — | 798,668 USD | — |
| Investing cash flowCash flow statement | — | -15,400 USD | — | — | — | — | — | — |
| Operating cash flowCash flow statement | — | -6,035,489 USD | — | — | -12,894,439 USD | — | -9,933,147 USD | — |
| Report source | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 03/16/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/12/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.